SiO2 Materials Science
SiO2 Materials Science is focused on three core segments: Pharmaceuticals, Molecular Diagnostics, and Consumer Healthcare. In the pharma segment, we solve more than 30 problems“ including some of the most challenging related to drug stability, drug efficacy, and safety. With the growth and adoption of biological drugs, nucleic acid-based vaccines, viral vectored therapies, and cell and gene therapies “ container surface chemistry and manufacturing flexibility play an increasingly critical role in drug product commercialization. In the molecular diagnostic segment, we introduce significant advances in blood preservation and genomic analysis that facilitate new possibilities in genomic testing and liquid biopsies. In the consumer healthcare segment, we provide innovative containers which combine the safety and durability of plastic with the oxygen and moisture barrier of glass.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Occupational Health
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
SiO2 Materials Science is a materials science company with deep roots in chemistry and engineering and developed by an interdisciplinary team of world class scientists, engineers, and product development experts.
- The SiO2 technology platform is protected with more than 300 patents entities covering close to 8000 patent use claims.
- Our products are molded from completely inert engineered polymers and incorporate a thin, glass-like barrier coating system on the inside surface.
- Our patented technology applies a unique glass-like barrier onto any plastic surface and is engineered to combine the durability and dimensional precision of plastic with the physical and barrier properties of glass.
- The SiO2 technology eliminates contaminants associated with immunogenic response such as: subvisible particles, metal ions, tungsten, adhesives, and oils.
- We use proprietary, advanced, material science, to bring our client’s innovation to life, providing an end-to-end solution from the design, engineering, molding, barrier coating, to packaging for our clients.
About Us
n 1910, the Abrams family led by Mauri Abrams embarked on a remarkable journey of “pioneering firsts” which have revolutionized highly regulated industries. In the 1950s, Bobby Abrams took the helm and built what was to be one of the largest dairy companies in the continental United States. Through numerous innovations – including the first integrated plastic milk jug and the first resealable milk carton spout – Bobby Abrams introduced a new paradigm of customer convenience to the dairy industry. As the inventor of the private label concept, Bobby also constructed a new way to bring fresher milk to families throughout the eastern United States.
As his second chapter, Bobby invented a series of molded plastic containers – including the desiccated plastic vial for diabetic strips, the infant sippy cup, and airtight vials for drugs for abuse testing. These inventions provided safe and innovative packaging for leading companies such as M&M Mars, Johnson & Johnson, Abbott Laboratories, Roche Diagnostics, Glaxo Smith Kline, and most of the world’s governmental agencies associated with athletic drug testing and national dairy boards.
In 2012, Bobby was approached by the Children’s Hospital at Stanford University. The hospital was unable to save the lives of 20-25 pre-mature babies each year. These infants where suffering from adverse reactions to sub-visible particles found in traditional glass syringes and vials of their medicines. Bobby, with the help of several leading scientists and Nobel Laureate groups started his mission to invent a completely inert container to house modern biological drugs. It was at this time that SIO2 Materials Science was born.
SiO2 has spent 10 years and more than $500 million in research and development to invent the breakthrough technology platform which fuses the benefits of glass and plastic without the drawbacks of either.
Why SiO2?
SiO2’s patented materials science is a combination of a plastic container with a microscopic (50 nanometers), thin, undetectable to the naked eye, pure glass coating for biological drugs and vaccines. Essentially combining the best of both glass and plastic without the drawbacks of either, but with the benefits of both.
“Many drug development and drug formulation innovations can be limited due to variables associated with traditional glass vials and syringes. The SiO2 vials and syringes eliminate these variables and allow drug development partners to bring their innovations to life.” – Dr. Robert S. Langer, institute professor at MIT
Essential characteristics of SiO2’s patented materials coating include thermal stability and integrity, chemical stability, a gas barrier, mechanical durability, no breakage, and precision molding. For the last 100 years, the pharmaceutical industry has had to choose glass or plastic and had to sacrifice attributes of one or the other. The SiO2 primary packaging platform for pharmaceutical drugs and vaccines is the only way to realize the possibility to have the best attributes of both glass and plastic.
Safer for patients & healthcare workers
- Reduced risk of immunogenicity (adverse patient side effects)
- No particles | No leachables & extractables | No metal ions | No silicone oil
- No breakage, shattering, or cracking of syringes or vials
Higher performance for pharmaceutical manufacturing & development
- Thermal stability range of -196˚C to 121˚C
- CCI / Seal integrity down to -80˚C
- Chemical stability pH ranges from 3-14
- No risk of delamination
- No breakage on filling lines or in supply chain
- Withstand 1,500 pounds of direct force
SiO2’s patented materials science was developed in Auburn, Alabama, over 10 years with the assistance of experts from four major U.S. research institutions, University of California, Santa Barbara and Berkeley, University of Chicago, MIT / Harvard. The company currently has over 300 patent entities and over 8000 patent claims.
“The SiO2 vials solve significant challenges in the commercialization of vaccines and biological drugs, which presently cannot be solved by glass or plastic vials. Bringing the SiO2 advanced material to market will enable pharmaceutical manufacturers to safely and more rapidly deploy their critical products.”
-Dr. Glenn Fredrickson, Professor of Chemical Engineering and Materials at the University of California, Santa Barbara